Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.30 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892867 | 0.91 | ABL1 (0.33) | PLATMTORRPTORMLST8 | |
| SCHEMBL6891861 | 0.85 | MTOR (0.42) | HSP90AA1PLATPIK3CAMTORRPTOR | |
| SCHEMBL6894476 | 0.85 | MTOR (0.34) | HSP90AA1PLATPIK3CAMTORRPTOR | |
| SCHEMBL6893520 | 0.83 | MTOR (0.42) | HSP90AA1PLATPIK3CAMTORRPTOR | |
| SCHEMBL10234759 | 0.80 | CHEK1 (0.43) | HSP90AA1PIK3CA | |
| SCHEMBL6893613 | 0.79 | MTOR (0.46) | PLATMTORRPTORMLST8 | |
| SCHEMBL10234742 | 0.78 | CHEK1 (0.35) | HSP90AA1PIK3CA | |
| SCHEMBL10234771 | 0.78 | CHEK1 (0.37) | HSP90AA1PIK3CAMTOR | |
| SCHEMBL10234416 | 0.78 | KDR (0.35) | HSP90AA1PIK3CAMTOR | |
| SCHEMBL10328276 | 0.78 | KDM4E (0.34) | PLATMTORRPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | HSP90AA1 2279/4885PLAT 4533/4885PIK3CA 33/4885 |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | HSP90AA1 2012/4885PLAT 2240/4885PIK3CA 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.